{"data":{"id":"10.6084/m9.figshare.c.2127254.v1","type":"dois","attributes":{"doi":"10.6084/m9.figshare.c.2127254.v1","prefix":"10.6084","suffix":"m9.figshare.c.2127254.v1","identifiers":[],"alternateIdentifiers":[],"creators":[{"name":"J. L. Delgado","affiliation":[],"nameIdentifiers":[]},{"name":"J. Estevez","affiliation":[],"nameIdentifiers":[]},{"name":"M. Radicioni","affiliation":[],"nameIdentifiers":[]},{"name":"L. Loprete","affiliation":[],"nameIdentifiers":[]},{"name":"J. Moscoso Del Prado","affiliation":[],"nameIdentifiers":[]},{"name":"C. Nieto Magro","affiliation":[],"nameIdentifiers":[]}],"titles":[{"title":"Pharmacokinetics and preliminary efficacy of two vaginal gel formulations of ultra-low-dose estriol in postmenopausal women"}],"publisher":"Figshare","container":{},"publicationYear":2015,"subjects":[{"subject":"Microbiology"},{"subject":"FOS: Biological sciences","schemeUri":"http://www.oecd.org/science/inno/38235147.pdf","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"FOS: Biological sciences","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"Cell Biology"},{"subject":"Physiology"},{"subject":"Pharmacology"},{"subject":"39999 Chemical Sciences not elsewhere classified","subjectScheme":"FOR"},{"subject":"FOS: Chemical sciences","schemeUri":"http://www.oecd.org/science/inno/38235147.pdf","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"FOS: Chemical sciences","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"Ecology"},{"subject":"Immunology"},{"subject":"FOS: Clinical medicine","schemeUri":"http://www.oecd.org/science/inno/38235147.pdf","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"FOS: Clinical medicine","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"Cancer"},{"subject":"Science Policy"},{"subject":"Infectious Diseases"},{"subject":"FOS: Health sciences","schemeUri":"http://www.oecd.org/science/inno/38235147.pdf","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"FOS: Health sciences","subjectScheme":"Fields of Science and Technology (FOS)"}],"contributors":[],"dates":[{"date":"2015-12-05","dateType":"Created"},{"date":"2016-04-25","dateType":"Updated"},{"date":"2015","dateType":"Issued"}],"language":null,"types":{"ris":"GEN","bibtex":"misc","citeproc":"article","schemaOrg":"Collection","resourceType":"Collection","resourceTypeGeneral":"Collection"},"relatedIdentifiers":[],"relatedItems":[],"sizes":[],"formats":[],"version":null,"rightsList":[{"rights":"CC-BY","rightsUri":"http://creativecommons.org/licenses/by/3.0/us"}],"descriptions":[{"description":"\u003cb\u003eObjectives\u003c/b\u003e To investigate the pharmacokinetics, safety and preliminary effectiveness of ultra-low-dose estriol vaginal gel formulations (20 μg/g (T1) and 50 μg/g (T2)) compared to Ovestinon® (estriol 500 μg/0.5 g (R)) and placebo in postmenopausal women. \u003cb\u003eMethods\u003c/b\u003e Forty-three volunteers were randomly assigned to received T1, T2, R or placebo once daily for 21 days. Absorption of estriol after single and multiple administration was analyzed. Cytological changes in the vagina, tolerability and safety were also investigated. \u003cb\u003eResults\u003c/b\u003e Thirty-six women were included in the pharmacokinetic analysis. Systemic absorption was lower with test formulations (AUC\u003csub\u003e0-\u003c/sub\u003e\u003ci\u003e\u003csub\u003et\u003c/sub\u003e\u003c/i\u003e: 171.65 ± 80.18 (T1) and 406.75 ± 199.53 (T2) pg/ml × h) than with Ovestinon® (1221.97 ± 549.06 pg/ml × h). Estriol exposure of the test formulations after multiple administration (AUC\u003csub\u003ess\u003c/sub\u003e: 36.33 ± 30.52 (T1) and 73.71 ± 46.86 (T2) pg/ml × h) was significantly lower than after single-dose administration and not significantly different between them. In contrast, the exposure after repeated administration of Ovestinon® was considerable and not statistically different from levels after single administration. All estriol formulations produced similar improvement in the vaginal maturation value, while placebo showed a small and not significant change. Overall safety and acceptability were good. \u003cb\u003eConclusions\u003c/b\u003e Estriol 20 and 50 μg/g formulations, while showing a comparable capacity for reversing vaginal atrophy, present a highly favorable safety profile, producing a very low systemic absorption of estriol and significantly lower than that of Ovestinon®.","descriptionType":"Abstract"}],"geoLocations":[],"fundingReferences":[],"xml":"PD94bWwgdmVyc2lvbj0iMS4wIiBlbmNvZGluZz0iVVRGLTgiPz4KPHJlc291cmNlIHhtbG5zOnhzaT0iaHR0cDovL3d3dy53My5vcmcvMjAwMS9YTUxTY2hlbWEtaW5zdGFuY2UiIHhtbG5zPSJodHRwOi8vZGF0YWNpdGUub3JnL3NjaGVtYS9rZXJuZWwtNCIgeHNpOnNjaGVtYUxvY2F0aW9uPSJodHRwOi8vZGF0YWNpdGUub3JnL3NjaGVtYS9rZXJuZWwtNCBodHRwOi8vc2NoZW1hLmRhdGFjaXRlLm9yZy9tZXRhL2tlcm5lbC00L21ldGFkYXRhLnhzZCI+CiAgPGlkZW50aWZpZXIgaWRlbnRpZmllclR5cGU9IkRPSSI+MTAuNjA4NC9NOS5GSUdTSEFSRS5DLjIxMjcyNTQuVjE8L2lkZW50aWZpZXI+CiAgPGNyZWF0b3JzPgogICAgPGNyZWF0b3I+CiAgICAgIDxjcmVhdG9yTmFtZT5KLiBMLiBEZWxnYWRvPC9jcmVhdG9yTmFtZT4KICAgIDwvY3JlYXRvcj4KICAgIDxjcmVhdG9yPgogICAgICA8Y3JlYXRvck5hbWU+Si4gRXN0ZXZlejwvY3JlYXRvck5hbWU+CiAgICA8L2NyZWF0b3I+CiAgICA8Y3JlYXRvcj4KICAgICAgPGNyZWF0b3JOYW1lPk0uIFJhZGljaW9uaTwvY3JlYXRvck5hbWU+CiAgICA8L2NyZWF0b3I+CiAgICA8Y3JlYXRvcj4KICAgICAgPGNyZWF0b3JOYW1lPkwuIExvcHJldGU8L2NyZWF0b3JOYW1lPgogICAgPC9jcmVhdG9yPgogICAgPGNyZWF0b3I+CiAgICAgIDxjcmVhdG9yTmFtZT5KLiBNb3Njb3NvIERlbCBQcmFkbzwvY3JlYXRvck5hbWU+CiAgICA8L2NyZWF0b3I+CiAgICA8Y3JlYXRvcj4KICAgICAgPGNyZWF0b3JOYW1lPkMuIE5pZXRvIE1hZ3JvPC9jcmVhdG9yTmFtZT4KICAgIDwvY3JlYXRvcj4KICA8L2NyZWF0b3JzPgogIDx0aXRsZXM+CiAgICA8dGl0bGU+UGhhcm1hY29raW5ldGljcyBhbmQgcHJlbGltaW5hcnkgZWZmaWNhY3kgb2YgdHdvIHZhZ2luYWwgZ2VsIGZvcm11bGF0aW9ucyBvZiB1bHRyYS1sb3ctZG9zZSBlc3RyaW9sIGluIHBvc3RtZW5vcGF1c2FsIHdvbWVuPC90aXRsZT4KICA8L3RpdGxlcz4KICA8cHVibGlzaGVyPkZpZ3NoYXJlPC9wdWJsaXNoZXI+CiAgPHB1YmxpY2F0aW9uWWVhcj4yMDE1PC9wdWJsaWNhdGlvblllYXI+CiAgPHJlc291cmNlVHlwZSByZXNvdXJjZVR5cGVHZW5lcmFsPSJDb2xsZWN0aW9uIj5Db2xsZWN0aW9uPC9yZXNvdXJjZVR5cGU+CiAgPHN1YmplY3RzPgogICAgPHN1YmplY3Q+TWljcm9iaW9sb2d5PC9zdWJqZWN0PgogICAgPHN1YmplY3Qgc3ViamVjdFNjaGVtZT0iRmllbGRzIG9mIFNjaWVuY2UgYW5kIFRlY2hub2xvZ3kgKEZPUykiIHNjaGVtZVVSST0iaHR0cDovL3d3dy5vZWNkLm9yZy9zY2llbmNlL2lubm8vMzgyMzUxNDcucGRmIj5GT1M6IEJpb2xvZ2ljYWwgc2NpZW5jZXM8L3N1YmplY3Q+CiAgICA8c3ViamVjdCBzdWJqZWN0U2NoZW1lPSJGaWVsZHMgb2YgU2NpZW5jZSBhbmQgVGVjaG5vbG9neSAoRk9TKSI+Rk9TOiBCaW9sb2dpY2FsIHNjaWVuY2VzPC9zdWJqZWN0PgogICAgPHN1YmplY3Q+Q2VsbCBCaW9sb2d5PC9zdWJqZWN0PgogICAgPHN1YmplY3Q+UGh5c2lvbG9neTwvc3ViamVjdD4KICAgIDxzdWJqZWN0PlBoYXJtYWNvbG9neTwvc3ViamVjdD4KICAgIDxzdWJqZWN0IHN1YmplY3RTY2hlbWU9IkZPUiI+Mzk5OTkgQ2hlbWljYWwgU2NpZW5jZXMgbm90IGVsc2V3aGVyZSBjbGFzc2lmaWVkPC9zdWJqZWN0PgogICAgPHN1YmplY3Qgc3ViamVjdFNjaGVtZT0iRmllbGRzIG9mIFNjaWVuY2UgYW5kIFRlY2hub2xvZ3kgKEZPUykiIHNjaGVtZVVSST0iaHR0cDovL3d3dy5vZWNkLm9yZy9zY2llbmNlL2lubm8vMzgyMzUxNDcucGRmIj5GT1M6IENoZW1pY2FsIHNjaWVuY2VzPC9zdWJqZWN0PgogICAgPHN1YmplY3Qgc3ViamVjdFNjaGVtZT0iRmllbGRzIG9mIFNjaWVuY2UgYW5kIFRlY2hub2xvZ3kgKEZPUykiPkZPUzogQ2hlbWljYWwgc2NpZW5jZXM8L3N1YmplY3Q+CiAgICA8c3ViamVjdD5FY29sb2d5PC9zdWJqZWN0PgogICAgPHN1YmplY3Q+SW1tdW5vbG9neTwvc3ViamVjdD4KICAgIDxzdWJqZWN0IHN1YmplY3RTY2hlbWU9IkZpZWxkcyBvZiBTY2llbmNlIGFuZCBUZWNobm9sb2d5IChGT1MpIiBzY2hlbWVVUkk9Imh0dHA6Ly93d3cub2VjZC5vcmcvc2NpZW5jZS9pbm5vLzM4MjM1MTQ3LnBkZiI+Rk9TOiBDbGluaWNhbCBtZWRpY2luZTwvc3ViamVjdD4KICAgIDxzdWJqZWN0IHN1YmplY3RTY2hlbWU9IkZpZWxkcyBvZiBTY2llbmNlIGFuZCBUZWNobm9sb2d5IChGT1MpIj5GT1M6IENsaW5pY2FsIG1lZGljaW5lPC9zdWJqZWN0PgogICAgPHN1YmplY3Q+Q2FuY2VyPC9zdWJqZWN0PgogICAgPHN1YmplY3Q+U2NpZW5jZSBQb2xpY3k8L3N1YmplY3Q+CiAgICA8c3ViamVjdD5JbmZlY3Rpb3VzIERpc2Vhc2VzPC9zdWJqZWN0PgogICAgPHN1YmplY3Qgc3ViamVjdFNjaGVtZT0iRmllbGRzIG9mIFNjaWVuY2UgYW5kIFRlY2hub2xvZ3kgKEZPUykiIHNjaGVtZVVSST0iaHR0cDovL3d3dy5vZWNkLm9yZy9zY2llbmNlL2lubm8vMzgyMzUxNDcucGRmIj5GT1M6IEhlYWx0aCBzY2llbmNlczwvc3ViamVjdD4KICAgIDxzdWJqZWN0IHN1YmplY3RTY2hlbWU9IkZpZWxkcyBvZiBTY2llbmNlIGFuZCBUZWNobm9sb2d5IChGT1MpIj5GT1M6IEhlYWx0aCBzY2llbmNlczwvc3ViamVjdD4KICA8L3N1YmplY3RzPgogIDxkYXRlcz4KICAgIDxkYXRlIGRhdGVUeXBlPSJDcmVhdGVkIj4yMDE1LTEyLTA1PC9kYXRlPgogICAgPGRhdGUgZGF0ZVR5cGU9IlVwZGF0ZWQiPjIwMTYtMDQtMjU8L2RhdGU+CiAgICA8ZGF0ZSBkYXRlVHlwZT0iSXNzdWVkIj4yMDE1PC9kYXRlPgogIDwvZGF0ZXM+CiAgPHNpemVzLz4KICA8Zm9ybWF0cy8+CiAgPHZlcnNpb24vPgogIDxyaWdodHNMaXN0PgogICAgPHJpZ2h0cyByaWdodHNVUkk9Imh0dHA6Ly9jcmVhdGl2ZWNvbW1vbnMub3JnL2xpY2Vuc2VzL2J5LzMuMC91cyI+Q0MtQlk8L3JpZ2h0cz4KICA8L3JpZ2h0c0xpc3Q+CiAgPGRlc2NyaXB0aW9ucz4KICAgIDxkZXNjcmlwdGlvbiBkZXNjcmlwdGlvblR5cGU9IkFic3RyYWN0Ij4mbHQ7YiZndDtPYmplY3RpdmVzJmx0Oy9iJmd0OyBUbyBpbnZlc3RpZ2F0ZSB0aGUgcGhhcm1hY29raW5ldGljcywgc2FmZXR5IGFuZCBwcmVsaW1pbmFyeSBlZmZlY3RpdmVuZXNzIG9mIHVsdHJhLWxvdy1kb3NlIGVzdHJpb2wgdmFnaW5hbCBnZWwgZm9ybXVsYXRpb25zICgyMCDOvGcvZyAoVDEpIGFuZCA1MCDOvGcvZyAoVDIpKSBjb21wYXJlZCB0byBPdmVzdGlub27CriAoZXN0cmlvbCA1MDAgzrxnLzAuNSBnIChSKSkgYW5kIHBsYWNlYm8gaW4gcG9zdG1lbm9wYXVzYWwgd29tZW4uICZsdDtiJmd0O01ldGhvZHMmbHQ7L2ImZ3Q7IEZvcnR5LXRocmVlIHZvbHVudGVlcnMgd2VyZSByYW5kb21seSBhc3NpZ25lZCB0byByZWNlaXZlZCBUMSwgVDIsIFIgb3IgcGxhY2VibyBvbmNlIGRhaWx5IGZvciAyMSBkYXlzLiBBYnNvcnB0aW9uIG9mIGVzdHJpb2wgYWZ0ZXIgc2luZ2xlIGFuZCBtdWx0aXBsZSBhZG1pbmlzdHJhdGlvbiB3YXMgYW5hbHl6ZWQuIEN5dG9sb2dpY2FsIGNoYW5nZXMgaW4gdGhlIHZhZ2luYSwgdG9sZXJhYmlsaXR5IGFuZCBzYWZldHkgd2VyZSBhbHNvIGludmVzdGlnYXRlZC4gJmx0O2ImZ3Q7UmVzdWx0cyZsdDsvYiZndDsgVGhpcnR5LXNpeCB3b21lbiB3ZXJlIGluY2x1ZGVkIGluIHRoZSBwaGFybWFjb2tpbmV0aWMgYW5hbHlzaXMuIFN5c3RlbWljIGFic29ycHRpb24gd2FzIGxvd2VyIHdpdGggdGVzdCBmb3JtdWxhdGlvbnMgKEFVQyZsdDtzdWImZ3Q7MC0mbHQ7L3N1YiZndDsmbHQ7aSZndDsmbHQ7c3ViJmd0O3QmbHQ7L3N1YiZndDsmbHQ7L2kmZ3Q7OiAxNzEuNjXigInCseKAiTgwLjE4IChUMSkgYW5kIDQwNi43NeKAicKx4oCJMTk5LjUzIChUMikgcGcvbWzigInDl+KAiWgpIHRoYW4gd2l0aCBPdmVzdGlub27CriAoMTIyMS45N+KAicKx4oCJNTQ5LjA2IHBnL21s4oCJw5figIloKS4gRXN0cmlvbCBleHBvc3VyZSBvZiB0aGUgdGVzdCBmb3JtdWxhdGlvbnMgYWZ0ZXIgbXVsdGlwbGUgYWRtaW5pc3RyYXRpb24gKEFVQyZsdDtzdWImZ3Q7c3MmbHQ7L3N1YiZndDs6IDM2LjMz4oCJwrHigIkzMC41MiAoVDEpIGFuZCA3My43MeKAicKx4oCJNDYuODYgKFQyKSBwZy9tbOKAicOX4oCJaCkgd2FzIHNpZ25pZmljYW50bHkgbG93ZXIgdGhhbiBhZnRlciBzaW5nbGUtZG9zZSBhZG1pbmlzdHJhdGlvbiBhbmQgbm90IHNpZ25pZmljYW50bHkgZGlmZmVyZW50IGJldHdlZW4gdGhlbS4gSW4gY29udHJhc3QsIHRoZSBleHBvc3VyZSBhZnRlciByZXBlYXRlZCBhZG1pbmlzdHJhdGlvbiBvZiBPdmVzdGlub27CriB3YXMgY29uc2lkZXJhYmxlIGFuZCBub3Qgc3RhdGlzdGljYWxseSBkaWZmZXJlbnQgZnJvbSBsZXZlbHMgYWZ0ZXIgc2luZ2xlIGFkbWluaXN0cmF0aW9uLiBBbGwgZXN0cmlvbCBmb3JtdWxhdGlvbnMgcHJvZHVjZWQgc2ltaWxhciBpbXByb3ZlbWVudCBpbiB0aGUgdmFnaW5hbCBtYXR1cmF0aW9uIHZhbHVlLCB3aGlsZSBwbGFjZWJvIHNob3dlZCBhIHNtYWxsIGFuZCBub3Qgc2lnbmlmaWNhbnQgY2hhbmdlLiBPdmVyYWxsIHNhZmV0eSBhbmQgYWNjZXB0YWJpbGl0eSB3ZXJlIGdvb2QuICZsdDtiJmd0O0NvbmNsdXNpb25zJmx0Oy9iJmd0OyBFc3RyaW9sIDIwIGFuZCA1MCDOvGcvZyBmb3JtdWxhdGlvbnMsIHdoaWxlIHNob3dpbmcgYSBjb21wYXJhYmxlIGNhcGFjaXR5IGZvciByZXZlcnNpbmcgdmFnaW5hbCBhdHJvcGh5LCBwcmVzZW50IGEgaGlnaGx5IGZhdm9yYWJsZSBzYWZldHkgcHJvZmlsZSwgcHJvZHVjaW5nIGEgdmVyeSBsb3cgc3lzdGVtaWMgYWJzb3JwdGlvbiBvZiBlc3RyaW9sIGFuZCBzaWduaWZpY2FudGx5IGxvd2VyIHRoYW4gdGhhdCBvZiBPdmVzdGlub27Cri48L2Rlc2NyaXB0aW9uPgogIDwvZGVzY3JpcHRpb25zPgo8L3Jlc291cmNlPgo=","url":"https://figshare.com/collections/Pharmacokinetics_and_preliminary_efficacy_of_two_vaginal_gel_formulations_of_ultra_low_dose_estriol_in_postmenopausal_women/2127254/1","contentUrl":null,"metadataVersion":5,"schemaVersion":"http://datacite.org/schema/kernel-4","source":"api","isActive":true,"state":"findable","reason":null,"viewCount":0,"viewsOverTime":[],"downloadCount":0,"downloadsOverTime":[],"referenceCount":0,"citationCount":0,"citationsOverTime":[],"partCount":0,"partOfCount":0,"versionCount":0,"versionOfCount":0,"created":"2015-12-05T21:21:47.000Z","registered":"2015-12-05T21:21:48.000Z","published":"2015","updated":"2024-12-15T14:15:51.000Z"},"relationships":{"client":{"data":{"id":"figshare.ars","type":"clients"}},"provider":{"data":{"id":"otjm","type":"providers"}},"media":{"data":{"id":"10.6084/m9.figshare.c.2127254.v1","type":"media"}},"references":{"data":[]},"citations":{"data":[]},"parts":{"data":[]},"partOf":{"data":[]},"versions":{"data":[]},"versionOf":{"data":[]}}}}